Stock ELABS ELLIPTIC LABORATORIES ASA
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Elliptic Laboratories ASA

Equities

ELABS

NO0010722283

Market Closed - Oslo Bors
Other stock markets
 10:45:00 2024-05-23 am EDT 		5-day change 1st Jan Change
15.22 NOK -5.47% Intraday chart for Elliptic Laboratories ASA -4.28% -10.68%
May. 23 Elliptic Laboratories ASA Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
May. 23 Transcript : Elliptic Laboratories ASA, Q1 2024 Earnings Call, May 23, 2024

Summary

  • From a short-term investment perspective, the company presents a deteriorated fundamental situation

Strengths

  • Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
  • Thanks to a sound financial situation, the firm has significant leeway for investment.
  • Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
  • The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.

Weaknesses

  • The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 48.79 times its estimated earnings per share for the ongoing year.
  • Based on current prices, the company has particularly high valuation levels.
  • The company appears highly valued given the size of its balance sheet.
  • For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
  • The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
  • For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
  • For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
  • Over the past four months, analysts' average price target has been revised downwards significantly.
  • The group usually releases earnings worse than estimated.

Ratings chart - Surperformance

Sector: Software

1st Jan change Capi. Investor Rating ESG Refinitiv
ELLIPTIC LABORATORIES ASA Stock Elliptic Laboratories ASA
-10.68% 158M -
ZSCALER, INC. Stock Zscaler, Inc.
-22.41% 26.1B
C
MONDAY.COM LTD. Stock monday.com Ltd.
+30.46% 12.06B -
KPIT TECHNOLOGIES LIMITED Stock KPIT Technologies Limited
-0.61% 4.91B
C
WALKME LTD. Stock WalkMe Ltd.
-18.28% 782M -
TRAFFIC CONTROL TECHNOLOGY CO., LTD. Stock Traffic Control Technology Co., Ltd.
+21.48% 638M -
XPERI INC. Stock Xperi Inc.
-15.88% 427M -
INSYDE SOFTWARE CORP. Stock Insyde Software Corp.
+6.74% 324M - -
JIADE LIMITED Stock JIADE Limited
0.00% 281M - -
ZHENGZHOU TIAMAES TECHNOLOGY CO.,LTD Stock Zhengzhou Tiamaes Technology Co.,Ltd
-26.14% 223M - -
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
-
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion
-

Business Predictability

Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
-
Earnings quality

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. ELABS Stock
  4. Ratings Elliptic Laboratories ASA